Skip to Main Content

Author Details

Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
2007
59
22
PMIDPaper TitleJournal TitlePublished Year
37872280Integrated genotype-phenotype analysis of familial adenomatous polyposis-associated hepatocellular adenomas.Virchows Arch2024
36562826BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.Cancer Immunol Immunother2023
37141769Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.Lung Cancer2023
37005590Comparing gene expression in deep infiltrating endometriosis with adenomyosis uteri: evidence for dysregulation of oncogene pathways.Reprod Biol Endocrinol2023
36445224Expanding the molecular spectrum of gene fusions in endometrial stromal sarcoma: Novel subunits of the chromatin remodeling complexes PRC2 and NuA4/TIP60 as alternative fusion partners.Genes Chromosomes Cancer2023
36635225First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.J Pathol Clin Res2023
34331337Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.Genes Chromosomes Cancer2022
35598358The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.Eur J Cancer2022
35681079Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).NPJ Precis Oncol2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
36207130Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.Cold Spring Harb Mol Case Stud2022
35058282Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.Cold Spring Harb Mol Case Stud2022
34863788The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.Gastroenterology2022
34325986Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Urol Oncol2022
34125345Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.Cancer Immunol Immunother2022
33318580Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma.Mod Pathol2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33520406A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.Oncoimmunology2021
33898315<i>De Novo</i> Versus Secondary Metastatic <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer.Front Oncol2021
33667718Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Lung Cancer2021
34408792Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.Ther Adv Med Oncol2021
34487971The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.ESMO Open2021
34605937Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie.Pathologe2021
33976623Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.Case Rep Oncol2021
32319699NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.Genes Chromosomes Cancer2020
31970771Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.Int J Cancer2020
32017710Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.J Clin Invest2020
31652375Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.Genes Chromosomes Cancer2020
32710569miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis.J Pathol2020
32923902Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer.JCO Precis Oncol2020
32280037High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.Urol Oncol2020
32212351Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.Genes Chromosomes Cancer2020
30446996Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.Int J Cancer2019
30238975Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.Int J Cancer2019
30255938Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma.Int J Cancer2019
30230086Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.Genes Chromosomes Cancer2019
31491926RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.Cancers (Basel)2019
31349062Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.J Thorac Oncol2019
31008532Variant classification in precision oncology.Int J Cancer2019
31139322Defining molecular risk in ALK<sup>+</sup> NSCLC.Oncotarget2019
30963573Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.Int J Cancer2019
30901310<i>RSPO2</i> gene rearrangement: a powerful driver of β-catenin activation in liver tumours.Gut2019
30653256Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.Int J Cancer2019
30669647Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.Cancers (Basel)2019
29044880Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.Genes Chromosomes Cancer2018
35135162Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.JCO Precis Oncol2018
30023099<i>EML4-ALK</i> V3, treatment resistance, and survival: refining the diagnosis of ALK<sup>+</sup> NSCLC.J Thorac Dis2018
30348504Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.Pathology2018
30505715Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.Transl Lung Cancer Res2018
29424427Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.Int J Cancer2018
  • 1 - 50 of 59

Recommended Authors

Ritika Kundra
Memorial Sloan Kettering Cancer Center
Career Start Year 2016
Number of shared co-authors 1
Xue Wu
Nanjing Geneseeq Technology Inc.
Career Start Year 2016
Number of shared co-authors 0
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 3
Daniel H Hovelson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 1
Jason D Peterson
Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center
Career Start Year 2014
Number of shared co-authors 0
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 2012
Number of shared co-authors 2
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 1
David A Moore
University College London Cancer Institute
Career Start Year 2012
Number of shared co-authors 2
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2011
Number of shared co-authors 3
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 2
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 2
Raymond S Lim
Memorial Sloan Kettering Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 0
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 1
Francine B de Abreu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 0
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 5
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 6
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 14
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 0
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 5
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 7
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 7
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 0
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 10
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 1

Collaborators

Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 55
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 43
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 39
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 29
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 28
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 24
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 23
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 23
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 17
Ivo Buchhalter
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers 7
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 6
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 5
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 5
Esther Herpel
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 5
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 5
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 4
Barbara Hutter
National Center for Tumor Diseases (NCT) Heidelberg
Co-authored papers 4
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 4
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 4
Thomas Albrecht
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 3
Hannah Goldschmid
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 3
Hans-Peter Sinn
Pathologisches Institut, Universitatsklinikum Heidelberg
Co-authored papers 3
Markus Ball
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 3
Cristina R Antonescu
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Christof von Kalle
Berlin Institute of Health at Charite-Universitatsmedizin Berlin
Co-authored papers 2
Daniel H??bschmann
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Co-authored papers 2
David J Burn
Population Health Sciences Institute, Newcastle University
Co-authored papers 2
Stephan Wolf
Co-authored papers 2
Simon Kreutzfeldt
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 2
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 2
Release 1.2